A modified form of EGCG called peracetate-protected EGCG has been developed as a precursor drug, which reduces VEGFA secreted by cancer cells and by TAM in endometrial carcinoma by inhibiting the PI3K/AKT/mTOR/HIF1 pathway and infiltration of VEGFA-expressing TAMs viaCXCL12 mediation in stromal cells [203]. The gene discussed is HIF1A; the disease is endometrial carcinoma.